title: Yellow fever vaccination and increased relapse rate in travelers with multiple sclerosis.
abstract: OBJECTIVE
  To investigate the effect of yellow fever (YF) immunization on the subsequent multiple sclerosis (MS) relapse risk.
  
  
  METHODS
  Self-controlled case series study.
  
  
  METHODS
  An MS outpatient clinic.
  
  
  METHODS
  Seven patients with clinical relapsing-remitting MS traveling to endemic YF areas who received the YF 17D-204 vaccine were studied.
  
  
  METHODS
  The YF 17D-204 vaccine.
  
  
  METHODS
  Number of relapses. Secondary outcomes included the number of new lesions on magnetic resonance imaging and peripheral mononuclear cell cytokine and chemokine production.
  
  
  RESULTS
  The annual exacerbation rate during risk periods following immunization was 8.57, while the relapse rate outside the risk period was only 0.67 (rate ratio = 12.778; P < .001). Three months after immunization, patients showed a significant increase in new or enlarging T2-weighted lesions and gadolinium-enhancing lesions compared with 12 months prior to vaccination and 9 months after immunization (both P < .001). Moreover, blood myelin basic protein and myelin oligodendrocyte glycoprotein responses showed significant increases in interferon γ-induced protein 10 kDa-, interferon γ-, interleukin 1α-, interleukin 1β-, and tumor necrosis factor-secreting cell numbers as well as complement component C1qB production after YF vaccination in patients with MS compared with unvaccinated patients with MS, patients with MS vaccinated against influenza, and healthy control subjects (P = .01 and P < .001, respectively).
  
  
  CONCLUSIONS
  For patients with MS traveling to endemic YF areas, vaccination should be recommended on the basis of carefully weighing the risk of exacerbation against the likelihood of exposure to the YF virus.
authors.affiliation: Department of Neurology, Institute for Neurological Research Dr Raúl Carrea, Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia, Buenos Aires, Argentina.
authors.forename: Mauricio F
authors.initials: MF
authors.lastname: Farez
authors.forename: Jorge
authors.initials: J
authors.lastname: Correale
mesh_terms: D000328:Adult; D001921:Brain / Q000473:pathology; D016207:Cytokines / Q000378:metabolism; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D004676:Myelin Basic Protein / Q000378:metabolism; D009185:Myelin Proteins / Q000378:metabolism; D063308:Myelin-Oligodendrocyte Glycoprotein; D010446:Peptide Fragments / Q000378:metabolism; D012306:Risk; D055502:Secondary Prevention; D014195:Travel; D015004:Yellow Fever / Q000517:prevention & control*; D022341:Yellow Fever Vaccine / Q000276:immunology*
chemical_list: D016207:Cytokines; D007155:Immunologic Factors; C571326:MOG protein, human; D004676:Myelin Basic Protein; D009185:Myelin Proteins; D063308:Myelin-Oligodendrocyte Glycoprotein; D010446:Peptide Fragments; D022341:Yellow Fever Vaccine